LAVAL, QC, Sept. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS) today announced that James R. Howard-Tripp, President and Chief Executive Officer of the Company, will present at the UBS Global Life Sciences Conference taking place September 27-30 at the Grand Hyatt Hotel in New York City. The Labopharm presentation is scheduled for 4:30 p.m. on Wednesday, September 29, 2004 in Ballroom D. A live webcast will be available at www.labopharm.com and www.ibb.ubs.com and will be archived until October 30, 2004. Please connect at least 15 minutes prior to the live webcast to ensure time to download required software. The UBS Global Life Sciences Conference will focus on the biotechnology, life sciences, media technology, and pharmaceutical fields. Over 300 companies from the United States, Europe and Asia-Pacific will present to an expected audience of over 3,000 attendees. About Labopharm Inc. Labopharm Inc. (TSX:DDS) is an international specialty pharmaceutical company focused on the development of drugs incorporating the Company's proprietary advanced controlled-release technology, Contramid(R). Contramid(R) can be applied to a wide variety of drugs in solid oral dosage form, improving their oral administration and performance and is used to develop products that are either bio-equivalent to existing, branded products, or are new branded products. The Company's pipeline includes a combination of both in-house and partnered programs with products both in clinical trials and in preclinical development. Labopharm is also developing implantable mini-tablets based on Contramid(R) for local administration of drugs and novel polymeric nano- delivery systems for delivery of water-insoluble and poorly bio-available drugs. For more information, please visit www.labopharm.com. This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward- looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of clinical studies, the uncertainties related to the regulatory process and the commercialization of the drug thereafter. Investors should consult the Corporation's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
SOURCE Labopharm Inc.